Generex Biotechnology subsidiary Antigen Express has reported promising early results in a Phase II trial of its breast cancer treatment. The vaccine, called AE37, cut the recurrence of breast cancer...
It's one thing to have developed a successful drug-delivery technology for a single drug. It's another thing to have that technology proven as a "platform" delivery method for many different types of
Claiming a multimillion-dollar appraisal for one of its immunotherapeutic drugs, Generex ($GNBT) is laying plans to spin off Antigen Express into an independent, publicly-traded company. The
Antigen Express, the vaccine subsidiary of Generex Biotechnology, has amended an agreement with the Henry M. Jackson Foundation for the Advancement of Military Medicine related to the ongoing Phase
Generex, a Toronto-based drug-delivery company, has received its 162nd patent related to its buccal delivery technology, the company announced in a release. The Canadian Patent No. 2,354,148 covers
Canada's Generex isn't at all happy with TheStreet and biotech analyst Adam Feuerstein's assessment of the company, and it's letting its displeasure be known--in the form of a $250 million lawsuit.
A U.S. and Swiss biotech company have formed a research collaboration to focus on new therapeutic cancer vaccines. Worcester, MA-based Generex and Switzerland's Pevion Biotech plan to initially